A Curated Platform of Equity & Options Market Intelligence
Select Page

Member Content

M&A Analysis: Biotech Neuro M&A

by | Oct 1, 2019

Alder Bio (ALDR) on 9/16 with a $2B acquisition from Lundbeck that came at an 85% premium and included a CVR. Lundbeck highlighted the fact that eptinezumab could be the first intravenous CGRP drug to come to market. The takeover centers on a near-ap...

Please login to continue reading this article.

Not a Member yet?
Subscribe to
OptionsHawk Premium
Subscribe

Options Hawk Max

$300 | 30 days

  • Options Hawk Trading Hub Live Chat
  • Hawk’s Market Blitz
  • Spotlight Trades (2 Per Week)
  • Market Recap
  • Weekly Earnings Snapshots
  • Live Mock Portfolio
  • 1 on 1 Access
  • Hawk’s Trader Toolbox
  • Street Research
  • OptionsHawk Research
  • Daily Options Radar
  • OptionHawk’s Weekly Radar Report
  • Options Hawk Market Outlook Access
  • Daily Earnings Grid
  • Weekly and Monthly OpEx Sheets
  • Notable Options Database
  • OptionsHawk Quarterly Market Brief

More About this Plan

Options Hawk Elite

$149 | 30 days

  • Hawk’s Market Blitz
  • Spotlight Trades (2 Per Week)
  • Market Recap
  • Weekly Earnings Snapshots
  • OptionsHawk Research
  • Daily Options Radar
  • OptionHawk’s Weekly Radar Report
  • Options Hawk Market Outlook Access
  • Daily Earnings Grid
  • OptionsHawk Quarterly Market Brief

More About this Plan